C
삼성제약
001360KOSPI49.5 / 100
Reference Date: 2026-10-23
Financial Score23.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 9.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Samsung Pharmaceutical operates in pharmaceutical manufacturing and sales, biopharma, and health food sectors, distributing a wide range of products including specialty and over-the-counter drugs. The company is advancing clinical trials for pancreatic cancer treatment GV1001 and Alzheimer's disease, with revenue reaching 460.7 billion KRW in 2025.
Number of Employees
87people
Average Salary
66.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
10.29Industry Average 15.006.5Point
Lower than industry avg (good)
PBR
0.98Industry Average 1.204.0Point
In line with industry avg
ROE
10.18Industry Average 8.004.0Point
In line with industry avg
Debt Ratio
3.37Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼5.4% (2-year basis)
Operating Profit Growth Rate
0.5 / 3
Avg ▼2.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -10.9% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (8%, downtrend)
Current 1,266Won52-week high 2,21052-week low 1,180
1-month return1.0Point
1m -9.31% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral투자판단관련주요경영사항 (진행성 핵상 마비 치료제 GV 1001의 국내 제2b/3상 임상시험계획서 변경승인 신청서 제출)2026-09-28